Westmore · UDRP decision
WIPO · Case No. D2013-0406

Buyxenicalonlinee.com

TransferWIPO-indexed · informational, not legal advice

The Panel ordered transfer of <buyxenicalonlinee.com>. It found the domain confusingly similar to the Complainant’s XENICAL mark because adding the generic terms “buy” and the misspelled “onlinee” did not distinguish it. The Respondent lacked rights or legitimate interests because the domain led users expecting the Complainant’s product to a website offering competing generic products. Registration and use were in bad faith under Policy paragraph 4(b)(iv), based on the intentional attraction of users for commercial gain through confusion, together with the apparently fictitious registration address and possible use of a pseudonym.

Outcome
Transfer
At a glance
Provider
WIPO
Outcome
Transfer
Decision date
2013-04-29
Panelist(s)
Snyder, Steven L.
Complainant
F. Hoffmann-La Roche AG
Respondent
Emelyanov Sergey Petrovich
Disputed domain(s)
buyxenicalonlinee.com
Citation weightrelies on 3 authorities
Domain history UDRP Intelligence

The timeline behind buyxenicalonlinee.com

Registration, the decision and the archived record of what this domain actually displayed — from public RDAP and the Internet Archive.

Westmore reconstructs the full history behind buyxenicalonlinee.com — from public RDAP and the Internet Archive — as part of UDRP Intelligence:

Registration → decision → today timeline
Archived Wayback evidence of what the site showed
Registry bad-faith signals
The live current registrant
Available in UDRP Intelligence
Verified public record
Outcome & remedy
Complaint granted. Panel ordered transfer of buyxenicalonlinee.com.
Reverse Domain Name Hijacking
No RDNH raised.
Westmore Insight

The case illustrates a direct pharmaceutical-targeting pattern in which a trademark is combined with purchase and online-related terms and used to divert consumers to competing generic products. The decision also shows that inaccurate or uncertain registrant information may reinforce a bad-faith finding when combined with clear commercial targeting, although the commercial diversion itself was the central conduct under Policy paragraph 4(b)(iv).

The three-part test
Identical or Confusingly SimilarMet
Rights or Legitimate InterestsMet
Registered and Used in Bad FaithMet

Result of record. The panel's reasoning and decisive facts behind each element are in the Intelligence dossier below.

Related decisions
Case details
Provider
WIPO
Outcome
Transfer
Decision date
2013-04-29
Panel
Snyder, Steven L.
Full decision
7 min read · hosted by Westmore

WIPO Arbitration and Mediation Center ADMINISTRATIVE PANEL DECISION F. Hoffmann-La Roche AG v. Emelyanov Sergey Petrovich Case No. D2013-0406 1. The Parties Complainant is F. Hoffmann-La Roche AG, Grenzacherstrasse Basel, Switzerland, represented internally. Respondent is Emelyanov Sergey Petrovich, Komsomolskaya, Kiev, Ukraine. 2. The Domain Name and Registrar The disputed domain name <buyxenicalonlinee.com> is registered with DomainContext, Inc. (the “Registrar”). 3. Procedural History The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on February 27, 2013. On February 28, 2013, the Center transmitted by email to the Registrar a request for registrar verification in connection with the disputed domain name. On March 11, 2013, the Registrar transmitted by email to the Center its verification response confirming that Respondent is listed as the registrant and providing the contact details. The Center verified that the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy” or “UDRP”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”). In accordance with the Rules, paragraphs 2(a) and 4(a), the Center formally notified Respondent of the Complaint, and the proceedings commenced on March 11, 2013. In accordance with the Rules, paragraph 5(a), the due date for Response was March 31, 2013. Respondent did not submit any response. Accordingly, the Center notified Respondent’s default on April 4, 2013. The Center appointed Steven L. Snyder as the sole panelist in this matter on April 18, 2013. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7. 4. Factual Background For twenty years, Complainant has used the XENICAL mark in connection with a weight-loss medication. Complainant’s mark has been registered in dozens of countries around the world and it has taken steps to protect its mark, as evinced by the filing of this and other UDRP proceedings. In 2013, many years after Complainant’s mark was first used, Respondent registered the disputed domain name <buyxenicalonlinee.com>. Until recently, the disputed domain name led to a website that ostensibly offered Internet users the chance to purchase generic versions of the XENICAL brand medication. Although Respondent provided a name and address when it registered the disputed domain name, the address is apparently fictitious: A leading delivery company could not locate the address and was unable to deliver correspondence to Respondent. There is also some confusion as to Respondent’s name. On the WhoIs record it appears that Respondent is named Petrovich Emelyanov Sergey. After the Complaint was filed, the Registrar informed the Center that “Petrovich” was the Respondent’s middle name. Respondent has chosen not to respond to the Complaint. 5. Parties’ Contentions A. Complainant Complainant describes itself as “one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics” and represents that it has operations in more than 100 countries. Since 1993, Complainant has used the XENICAL mark in connection with a prescription weight-loss medication “used to help obese people lose weight and keep this weight off.” In a “multitude of countries worldwide,” Complainant has protected its XENICAL mark through numerous registrations, including International Registrations Nos. 612908 and 699154. Not surprisingly, Complainant argues that the disputed domain name <buyxenicalonlinee.com> is “confusingly similar” to its registered mark. The addition of the generic terms “buy” and “online” (which is misspelled as “onlinee”) do not, Complainant contends, lessen the confusion. Respondent does not have any rights or legitimate interests in the disputed domain name <buyxenicalonlinee.com>, Complainant argues, noting that it owns the XENICAL registrations and stating that it has never consented to Respondent’s use of this mark in any domain name. In Complainant’s view, “Respondent’s only reason in registering and using the contested Domain Name is to benefit from the reputation of the trademark XENICAL and illegitimately trade on its fame for commercial gain and profit.” Complainant argues that Respondent has registered and used the disputed domain name <buyxenicalonlinee.com> in bad faith. Respondent was undoubtedly aware of the XENICAL mark before he registered the disputed domain name. He has used the domain name to attract Internet users to his websites “by creating a likelihood of confusion with the Complainant’s well-known mark as to the source, affiliation and endorsement of Respondent’s website or of the products or services posted on or linked to Respondent’s website.” Once Internet users land on his webpage, they are offered generic versions of Complainant’s product. Based on these arguments, Complainant asks that the disputed domain name <buyxenicalonlinee.com> be transferred to its ownership. B. Respondent Respondent did not reply to Complainant’s contentions. 6. Discussion and Findings To obtain the transfer of a disputed domain name, a complainant must prove three elements, regardless of whether the respondent files a response to the complaint. The first element is that the “domain name is identical or confusingly similar to a trademark or service mark in which the complainant has rights.” Policy paragraph 4(a)(i). The second element a complainant must prove is that the registrant has “no rights or legitimate interests in respect of the domain name.” Paragraph 4(a)(ii). The third element for a complainant to establish is that the disputed “domain name has been registered and is being used in bad faith.” Paragraph 4(a)(iii). Complainant has proven all three elements. A. Identical or Confusingly Similar The disputed domain name <buyxenicalonlinee.com> is confusingly similar to Complainant’s well-known mark, XENICAL. The addition of generic terms such as “buy” and “online” do not distinguish the domain name from the mark. See LEGO Juris A/S v. PrivacyProtect.org / Kim Bum LLC , WIPO Case No. D2012-2462 (“the addition of descriptive terms to a trademark is generally not a distinguishing feature….”). B. Rights or Legitimate Interests It may be difficult for a complainant to prove the second element if the respondent is using the domain name “in connection with a bona fide offering of goods or services.” See Policy paragraph 4(c) in this case, Complainant faces no such difficulty: Prior to the submission of the Complaint, Respondent was using Complainant’s mark to lead Internet users to a website that promised to sell Complainant’s products but that instead sold competing products. Respondent has no rights or legitimate interests to so use the disputed domain name. See Compagnie Générale des Etablissements Michelin v. PrivacyProtect.org and Kim Bum LLC , WIPO Case No. D2013-0181 (“Neither of the Respondents has a right or legitimate interest in luring consumers to a website under false pretenses and then profiting from their presence at the website.”). C. Registered and Used in Bad Faith The UDRP states that one way for a complainant to prove bad-faith registration and use is to show the Respondent has “intentionally attempted to attract, for commercial gain, Internet users to [the] web site or other on-line location, by creating a likelihood of confusion with the complainant's mark as to the source, sponsorship, affiliation, or endorsement of [the] web site or location or of a product or service on [the] web site or location.” Policy paragraph 4(b)(iv). Complainant has made this showing. Many years after Complainant’s mark was registered around the world in connection with a prescription weight-loss medication, Respondent created the disputed domain name <buyxenicalonlinee.com>. Respondent simply took the well-known mark, bracketed it with generic words, and then linked the newly registered domain name to a website that apparently offered generic medications that were in direct competition with Complainant’s brand-name medication. In an apparent effort to cover its tracks, Respondent used a fictitious address when registering the domain name and may have used a pseudonym as well. This is further evidence of Respondent’s bad-faith registration and use. See Pfizer Inc. v. jg a/k/a Josh Green , WIPO Case No. D2004-0784 (“Respondent’s use of the domain names to promote the sales of products in competition with PFIZER’s products constitutes bad faith.”). 7. Decision For the foregoing reasons, in accordance with paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the disputed domain name <buyxenicalonlinee.com> be transferred to Complainant. Steven L. Snyder Sole Panelist Date: April 29, 2013

Source of record: WIPO . Reproduced for research; WIPO is the authoritative source.

Beyond the decision

What Westmore sees around buyxenicalonlinee.com

The decision is only the record. Westmore connects it to the cases, authorities, panelists, parties and domain evidence surrounding it.

Connected to Westmore UDRP Intelligence
115,898 decisions · citations · panelists · parties · domain history
Eleanor · UDRP intelligence
Ask Eleanor about this decision
Ask Eleanor about this decision

A short, grounded explanation drawn only from this decision's record — not legal advice or a prediction.

Unlocking Eleanor for this case uses 1 of your complimentary Intelligence unlocks· 3 remaining

Grounded in the Westmore record for this decision. Research/informational only — not legal advice or a prediction of any outcome.

Westmore Professional · Unlock the intelligence

The decision is only the beginning.

You've seen what happened. Now discover the deeper intelligence behind the case, the panelist, the parties and the authorities that matter.

Citation Intelligence
How this decision is cited and treated across the corpus.
Panelist Intelligence
The panel's tendencies, outcomes and reasoning patterns.
Domain History
Ownership chronology — creation vs. respondent acquisition.
Opposing-Party Research
Complainant, counsel and portfolio context.
Independent Case Review
Eleanor challenges your filing before the other side does.
Professional Matters
Open, research and manage matters end to end.
$395/month
Unlock Westmore Professional Annual & firm seats available · cancel anytime
Take the next step
Westmore UDRP · find the right service

Westmore UDRP records draw on WIPO-indexed decisions and are provided for research and informational purposes only. Not legal advice, a clearance opinion, or a prediction of any outcome.

Confidential buyer-side representation for premium-domain acquisitions.

LinkedIn
Insights
Briefs
Who Owns
Westmore
Research
Services
UDRP
Support
Buyer-side only· Escrow-protected· NDA on request

© 2026 Westmore. All rights reserved.

A note on privacy

Westmore uses a few essential cookies to keep this site secure and running smoothly. Nothing about your identity or interest is ever sold or shared.